Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(uridine triacetate)
41 results
  • Capecitabine-induced cerebellar toxicity and TYMS pharmacogenetics. [Journal Article]
    Anticancer Drugs 2019; 30(4):431-434Saif MW
  • Capecitabine, an oral prodrug of 5-fluorouracil (5-FU) is extensively used to treat many solid tumors, particularly breast and colorectal cancers. Neurotoxicity of capecitabine has been rarely reported as peripheral neuropathy, cerebellar syndrome, and multifocal leukoencephalopathy. Although very little is known about the pathogenetic mechanisms responsible for this toxicity, dihydropyrimidine d…
  • Fluoropyrimidine-induced cardiotoxicity. [Review]
    Crit Rev Oncol Hematol 2018; 124:1-10Depetris I, Marino D, … Leone F
  • Fluoropyrimidines (5-fluorouracil and capecitabine) are antimetabolite drugs, widely used for the treatment of a variety of cancers, both in adjuvant and in metastatic setting. Although the most common toxicities of these drugs have been extensively studied, robust data and comprehensive characterization still lack concerning fluoropyrimidine-induced cardiotoxicity (FIC), an infrequent but potent…
  • Case report of capecitabine toxicity and use of uridine triacetate. [Journal Article]
    J Oncol Pharm Pract 2017; :1078155217730662Oliver WD, Duffy AP, Hausner PF
  • Fluorouracil and capecitabine are fluoropyrimidine chemotherapy agents that are commonly used for various cancers. These agents are generally well tolerated at standard doses; however, it has been reported that 31-34% of patients develop dose-limiting toxicities. Dihydropyrimidine dehydrogenase and thymidylate synthase play a major role in fluorouracil and capecitabine activity and toxicity. Urid…
New Search Next